SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer
Journal of Clinical Oncology | Jan 13, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
European Heart Journal | Jan 13, 2019
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers
Gynecologic Oncology | Jan 13, 2019
Positive response to tolvaptan treatment would be a good prognostic factor for cirrhotic patients with ascites
Digestive Diseases | Jan 13, 2019
Most read this week